We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada (TOTEM)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00323492
First Posted: May 9, 2006
Last Update Posted: January 20, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Gilead Sciences
Results First Submitted: March 20, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: HIV Infections
Interventions: Drug: Truvada
Drug: Current HAART regimen

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Truvada Truvada + nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI).
Maintain Baseline Regimen Maintain baseline regimen.
Delayed Truvada Truvada + NNRTI or PI (participants from the control group who switched NRTIs to Truvada during Study Phase 2).

Participant Flow for 2 periods

Period 1:   Study Phase 1
    Truvada   Maintain Baseline Regimen   Delayed Truvada
STARTED   47   45   0 [1] 
Intent-to-Treat (ITT) Analysis Set   46 [2]   45   0 
COMPLETED   45   45   0 
NOT COMPLETED   2   0   0 
Adverse Event                2                0                0 
[1] Not applicable to Phase 1.
[2] One subject was excluded from ITT analysis set due to protocol violation.

Period 2:   Study Phase 2
    Truvada   Maintain Baseline Regimen   Delayed Truvada
STARTED   44 [1]   18 [2]   25 [3] 
COMPLETED   40   17   24 
NOT COMPLETED   4   1   1 
Adverse Event                1                0                0 
Physician Decision                1                0                0 
Lost to Follow-up                1                0                0 
Withdrawal by Subject                0                1                0 
Noncompliance with study schedule                0                0                1 
Protocol Violation                1                0                0 
[1] 1/45 subjects completed Phase 1 but did not start Phase 2. Week 48 ITT N=46
[2] 2/45 subjects completed Phase 1 but did not start Phase 2. Week 48 ITT N=20 (no switch to Truvada)
[3] N=25 switched to Truvada in Phase 2.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Truvada Truvada + NNRTI or PI.
Maintain Baseline Regimen Maintain baseline regimen.
Total Total of all reporting groups

Baseline Measures
   Truvada   Maintain Baseline Regimen   Total 
Overall Participants Analyzed 
[Units: Participants]
 47   45   92 
Age 
[Units: Years]
Median (Inter-Quartile Range)
 49.0 
 (42.0 to 58.0) 
 43.0 
 (39.0 to 50.0) 
 47.0 
 (41.0 to 55.0) 
Gender 
[Units: Participants]
     
Female   8   4   12 
Male   39   41   80 
Region of Enrollment 
[Units: Participants]
     
France   47   45   92 
Participants with plasma HIV-1 RNA < 400 copies/mL [1] 
[Units: Participants]
 47   45   92 
[1] At screening
Cluster determinant 4 (CD4) cell count [1] 
[Units: Cells/mm^3]
Median (Inter-Quartile Range)
 467 
 (314 to 698) 
 559 
 (337 to 714) 
 528 
 (318 to 709) 
[1] At screening
Low density lipoprotein cholesterol (LDL-CHO) [1] 
[Units: mmol/L]
Median (Inter-Quartile Range)
 4.0 
 (3.2 to 4.7) 
 4.0 
 (3.6 to 4.8) 
 4.0 
 (3.4 to 4.7) 
[1] Centralized laboratory assessment
Triglycerides [1] 
[Units: mmol/L]
Median (Inter-Quartile Range)
 2.3 
 (1.9 to 4.0) 
 2.7 
 (1.9 to 3.6) 
 2.4 
 (1.9 to 3.7) 
[1] Centralized laboratory assessment


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline to Week 12 in Fasting Triglycerides   [ Time Frame: Baseline to Week 12 ]

2.  Primary:   Change From Baseline to Week 12 in Fasting Low-density Lipoprotein Cholesterol (LDL-CHO)   [ Time Frame: Baseline to Week 12 ]

3.  Secondary:   Change From Baseline to Week 12 in Fasting High-density Lipoprotein Cholesterol (HDL-CHO)   [ Time Frame: Baseline to Week 12 ]

4.  Secondary:   Change From Baseline to Week 12 in Fasting Total Cholesterol (T-CHO)   [ Time Frame: Baseline to Week 12 ]

5.  Secondary:   Change From Baseline to Week 12 in Fasting T-CHO/HDL-CHO   [ Time Frame: Baseline to Week 12 ]

6.  Secondary:   Change From Baseline to Week 12 in Fasting HDL-CHO/LDL-CHO   [ Time Frame: Baseline to Week 12 ]

7.  Secondary:   Change From Baseline to Week 12 in Fasting Ultra-sensitive C-reactive Protein (Us-CRP)   [ Time Frame: Baseline to Week 12 ]

8.  Secondary:   Percentage of Participants With Fasting Plasma Triglycerides > 10 g/L (> 11.29 mmol/L) at Week 12   [ Time Frame: 12 weeks ]

9.  Secondary:   Change From Baseline to Week 12 in Cluster Determinant 4 (CD4) Cell Count   [ Time Frame: Baseline to Week 12 ]

10.  Secondary:   Change From Baseline to Week 48 in CD4 Cell Count   [ Time Frame: Baseline to Week 48 ]

11.  Secondary:   Percentage of Participants With Virologic Control (Plasma HIV-1 Ribonucleic Acid [RNA] < 400 Copies/mL) at Week 12   [ Time Frame: 12 weeks ]

12.  Secondary:   Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to 400 Copies/mL at Week 12   [ Time Frame: 12 weeks ]

13.  Secondary:   Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48   [ Time Frame: 48 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Comparison of adverse events between Truvada and maintain baseline regimen groups is inappropriate since numbers at risk (and exposure to study drug) are not balanced, as described in the adverse event treatment group descriptions.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Camille Aubron-Olivier
Organization: Gilead Sciences
phone: +33(0)1 42 737130
e-mail: camille.aubron-olivier@gilead.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Camille Aubron-Olivier, Gilead Sciences
ClinicalTrials.gov Identifier: NCT00323492     History of Changes
Other Study ID Numbers: GS-FR-164-0109
First Submitted: May 5, 2006
First Posted: May 9, 2006
Results First Submitted: March 20, 2009
Results First Posted: December 23, 2009
Last Update Posted: January 20, 2010